首页> 外文期刊>British journal of neurosurgery >The sequential use of carmustine wafers (Gliadel(R)) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
【24h】

The sequential use of carmustine wafers (Gliadel(R)) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.

机译:卡莫司汀薄饼的顺序使用(Gliadel(R))和术后伴随替莫唑胺和替莫唑胺辅助治疗的放射治疗:临床综述。

获取原文
获取原文并翻译 | 示例
           

摘要

In patients with glioblastoma multiforme (GBM), there is no consensus on the sequential use of two existing regimens: post-operative Gliadel implantation into the surgical cavity and concomitant temozolomide with radiotherapy followed by adjuvant temozolomide ('Stupp protocol'). NICE in the guideline TA121 (July 2007) could not pass any judgement on the sequential use of both the regimens due to lack of evidence at the time of consultation. Since then, few prospective studies and retrospective series have been reported using these two regimens sequentially. Except in one study, results were indicative of an incremental gain of 2-3 months in median survival in comparison to the published results using Gliadel or 'Stupp Protocol' alone. Post-surgical complications were manageable and within an acceptable range, when the sequential regimen was managed under defined guidelines and surgery was performed in a high volume centre. Moderate degree of increased myelosuppression has been reported in few series, however. In the absence of a phase III trial and the small number of patients in each series, the reported trend of toxicities and efficacy could only be substantiated by setting up a national database. Contributing to such a national database and toxicity recording could be made mandatory through peer review programme for the neurooncological services. Based on the preclinical and albeit lower level of clinical evidence, demonstrating temporal and spatial co-operation between two regimens (Gliadel and 'Stupp Protocol'), resulting in incremental 2-3 months median survival gain, should enable NICE in its next review to issue a favourable guidance. Depending on the number of patients eligible for such a sequential regimen, which could be 15%-25% of Glioblastoma patients diagnosed in England per annum, the additional annual cost of concomitant temozolomide would be approximately pound640,000 to pound1 million.
机译:在多形性胶质母细胞瘤(GBM)的患者中,关于序贯使用两种现有方案尚无共识:手术后将Gliadel植入手术腔内,并伴以替莫唑胺与放疗,再辅以替莫唑胺(“ Stupp方案”)。由于咨询时缺乏证据,NICE指南TA121(2007年7月)无法对两种方案的顺序使用作出任何判断。从那以后,很少有前瞻性研究和回顾性系列报道相继使用这两种方案。除一项研究外,与仅使用Gliadel或“ Stupp方案”发表的结果相比,结果表明中位生存期可增加2-3个月。如果按照已定义的指南对序贯方案进行管理,并在大容量中心进行手术,则术后并发症可以控制并且在可接受的范围内。然而,已经有少数系列报道了中等程度的骨髓抑制增加。在缺乏III期临床试验且每个系列患者较少的情况下,只能通过建立国家数据库来证实所报道的毒性和疗效趋势。通过神经肿瘤学的同行评审计划,可以强制要求为此类国家数据库和毒性记录做贡献。基于临床前和较低水平的临床证据,证明两种方案(Gliadel和“ Stupp方案”)之间在时间和空间上的合作可导致2-3个月的中位生存期增加,这将使NICE在下一次评估中发布有利的指导。根据符合这种连续治疗方案的患者人数(可能是每年在英格兰诊断出的胶质母细胞瘤患者的15%-25%),相应的替莫唑胺的额外年度费用约为64万英镑至100万英镑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号